Glenmark Pharmaceuticals Inc., USA to launch Micafungin for Injection USP, 50 mg/vial and 100 mg/vial

Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the upcoming launch1 of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial). Glenmark's Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial) is bioequivalent and therapeutically equivalent to the reference listed drug, Mycamine® for Injection, 50 mg/vial and 100 mg/vial, of Astellas Pharma US, Inc. NDA - 021506 and the company will begin distribution in September 2025.

According to IQVIA® sales data for the 12-month period ending June 2025, the Mycamine® for Injection, 50 mg/vial and 100 mg/vial market3 achieved annual sales of approximately $60.7 million*.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, "We are excited to announce the launch of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial), growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring quality and affordable alternatives to market for patients in need."

Glenmark's Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial) is only approved for the indication(s) listed in Glenmark's approved label.

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 1974.40 as compared to the previous close of Rs. 2043.95. The total number of shares traded during the day was 70689 in over 5106 trades.

The stock hit an intraday high of Rs. 2041.50 and intraday low of 1949.00. The net turnover during the day was Rs. 140913536.00.

All brand names and trademarks are the property of their respective owners.

Market includes brand and all available therapeutic equivalents. Note: IQVIA® data obtained by Glenmark is only available for all approved RLD indications. Glenmark's product is only approved for the indications listed in Glenmark's approved label and is not marketed for all RLD indications.

*IQVIA® National Sales Perspectives: Retail & Non-Retail, June 2025

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 USA Launch Micafungin Injection